BioVie, Inc. filings document a Nevada clinical-stage biopharmaceutical company with Nasdaq-listed Class A common stock and, in certain filings, warrants tied to its capital structure. Material-event reports cover securities offerings, underwriting agreements and issuances involving units, pre-funded units and warrants.
Proxy statements and related 8-K filings describe annual meeting voting matters, director elections, board appointments and amendments to the company’s omnibus equity incentive plan. Registration statement amendments provide formal disclosure for offering activity and financial-statement periods associated with BioVie’s development-stage operations.
BioVie Inc. (BIVI) scheduled its virtual 2026 annual meeting for November 10, 2026. Stockholders will vote on six incumbent director nominees, ratification of EisnerAmper LLP as auditor, and an amendment to the 2019 Omnibus Equity Incentive Plan. If approved, shares available for future awards under the plan would increase from 399,509 to 3,100,000. The company describes the proposed amount as approximately 27% of its issued and outstanding common stock on a fully diluted basis, using outstanding options and restricted stock units and the proposed additional shares in the calculation.
As of the September 21, 2026 record date, 8,682,710 shares were outstanding and entitled to vote; a quorum requires 2,894,237 shares represented. Directors are elected by plurality vote, while the auditor and plan proposals require a majority of votes cast. The meeting will be held online, with no in-person attendance, and the Board recommends voting for each nominee and each other proposal.
BioVie Inc. (BIVI) entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell, from time to time, shares of its Class A common stock with an aggregate offering price of up to $6,464,341 in an at-the-market offering under its effective Form S-3 shelf registration. The Agent may effect sales on or through The Nasdaq Capital Market or other U.S. trading markets, or in negotiated transactions, using commercially reasonable efforts on terms mutually agreed with BioVie. BioVie will pay the Agent a 3.0% commission on gross proceeds and reimburse specified expenses, and intends to use any net proceeds for general corporate purposes. The program will end upon the earlier of selling all Placement Shares, expiration of the registration statement on the third anniversary of its June 29, 2026 effectiveness, or termination of the agreement by either party; BioVie has no obligation to sell any shares and may suspend or terminate offerings at any time.
BioVie Inc. (BIVI) is adding equity flexibility through an at-the-market offering program of up to $6,464,341 of Class A common stock under a sales agreement with A.G.P./Alliance Global Partners, which will act as sales agent or principal and earn a 3.0% commission on gross proceeds.
Shares may be sold from time to time on Nasdaq or other permitted markets at prevailing prices, subject to Form S-3 General Instruction I.B.6 limits tied to BioVie’s non-affiliate market value. At an illustrative price of $2.07, selling 3,122,870 shares would raise the full amount, increasing as further adjusted net tangible book value per share from $1.34 to $1.51 and implying immediate dilution of $0.56 per share to new investors.
Net proceeds are intended for general corporate purposes, including funding BioVie’s clinical programs in neurodegenerative disease, long COVID and liver cirrhosis. The company’s auditors highlight substantial doubt about its ability to continue as a going concern, underscoring reliance on capital markets such as this ATM program.
BIOVIE INC. (BIVI) received a Schedule 13G filing reporting that Jane Street Group, LLC and its subsidiaries collectively beneficially own 441,751 shares of Class A Common Stock, representing 5.2% of the class as of August 28, 2026. All of these shares are held with shared voting and dispositive power, with no sole voting or dispositive authority reported.
BIOVIE INC. (BIVI) reported that Chief Medical Officer Joseph M. Palumbo purchased common stock. On 2026-08-28 he bought 4,843 shares of common stock in open market transactions at $2.16 per share, bringing his directly held position to 6,036 shares.
The shares were acquired in several open market trades, all executed at the same price.
BIOVIE INC. (BIVI) director Amy Suzon Chappell purchased 727 shares of Common Stock on 2026-08-28 in an open market transaction at $2.16 per share. Following this reported transaction, she directly owns 727 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that its Chief Financial Officer, Joanne Wendy Kim, purchased 2,500 shares of common stock in an open market transaction on 2026-08-28 at a price of $2.18 per share. Following this purchase, she directly holds 3,441 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that President & CEO Cuong V. Do purchased common stock on August 27, 2026. He bought 15,210 shares of BioVie common stock in open market transactions at a weighted average price of $2.08 per share, with trade prices ranging from $2.05 to $2.10. Following this purchase, he directly holds 16,117 common shares of BioVie.
BIOVIE INC. (BIVI) is reported to have a significant shareholder, Alta Partners LLC, which has filed a Schedule 13G indicating beneficial ownership of 687,321 shares of Class A Common Stock, all issuable upon exercise of warrants.
Alta Partners LLC reports this position as representing 8.4% of the outstanding Class A Common Stock, with sole voting and sole dispositive power over all 687,321 shares and no shared voting or dispositive power.
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases (Parkinson’s, Alzheimer’s, Long COVID) and advanced liver disease. It is conducting a primary securities offering of up to 16,025,641 shares of Common Stock, up to 16,025,641 Pre-funded Warrants, and up to 16,025,641 Common Warrants on a best efforts basis, with no minimum raise. Each share or Pre-funded Warrant is sold together with one Common Warrant, assumed at a combined price of $1.56, with Common Warrants exercisable at $1.95 for five years. Estimated net proceeds of about $22.7 million are intended for working capital, R&D and general corporate purposes. Recent SUNRISE-PD Phase 2b data in early Parkinson’s disease met prespecified biomarker and clinical endpoints, and a $13.1 million U.S. Department of War grant supports a Phase 2 Long COVID trial. Liver candidate BIV201 has FDA Fast Track and Orphan Drug status for ascites in cirrhosis.